17 September 2021

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

New Research Agreement with the University of York for Cancer Tests

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has entered into a new research agreement with the University of York for the development and validation of molecular tools with potential applications in cancer diagnosis and therapy.

The Company's wholly owned subsidiary Cizzle Biotechnology Limited was a spin out from the University of York based on original research and development undertaken in laboratories at the University, under the direction of Professor Dawn Coverley. The new agreement extends that relationship and provides seconded staff and access to the University's state of the art research facilities to support reagent generation work in collaboration with our recently announced Contract Research Organisation (CRO) partner Fairjouney Biologics.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "We are thrilled to be able to cement our long-standing relationship with the University of York, a member of the Russell Group of research-intensive universities and one of the world's premier institutions for inspirational and life-changing research. This new agreement will provide valuable additional resource and capability for developing our blood test for the early detection of lung cancer, and potentially other forms of cancer."

Enquiries:

Cizzle Biotechnology Holdings plc Allan Syms (Executive Chairman)	**Via IFC Advisory**
Allenby Capital Limited John Depasquale Alex Brearley	**+44(0) 20 33285656**
Novum Securities Limited Colin Rowbury Jon Bellis	**+44(0) 20 7399 9400**
IFC Advisory Limited Tim Metcalfe Florence Chandler	**+44(0) 20 3934 6630**

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally

occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.

For more information please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.